关键词:

代谢相关脂肪性肝病, 肥胖, 小儿健脾化浊消脂方, 维生素D, 脾虚失运

Abstract:

Objective　To investigate the efficacy of pediatric spleen-strengthening, turbidity-resolving and fat-reducing formula combined with vitamin D in the treatment of children with obesity-related metabolic fatty liver disease of spleen deficiency and impaired transportation type. Methods　This study is a prospective, single-center, controlled study. A total of 118 children diagnosed with obesity-related metabolic fatty liver disease of spleen deficiency and impaired transportation type were selected from Ankang Traditional Chinese Medicine Hospital between January and October 2024. They were randomly divided into a control group and an observation group, with 59 cases in each group. There were 31 males and 28 females in the control group, aged (11.41±2.21) years. There were 34 males and 25 females in the observation group, aged (11.67±2.58) years old. Both groups received a comprehensive intervention focused on a reasonable dietary structure and oral silymarin capsules. The control group also received oral vitamin D drops, while the observation group received the pediatric spleen-strengthening, turbidity-resolving and fat-reducing formula in addition to the treatment in the control group. Both groups were treated continuously for 12 weeks. Clinical efficacy, blood lipids [total cholesterol (TC) and triglycerides (TG)], liver function [aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB)], body mass index (BMI), liver/spleen CT ratio, and traditional Chinese medicine syndrome scores were compared, along with the recording of adverse reactions. Statistical analysis was performed using χ² and t tests. Results　The overall effective rate in the observation group was 94.92% (56/59), compared to 79.66% (47/59) in the control group, with a statistically significant difference (χ²=6.186, P=0.013). After treatment, the observation group's TC, TG, and BMI were (3.72±0.29) mmol/L, (1.48±0.19) mmol/L, and (24.86±2.02) kg/m², respectively, while the control group's values were (4.18±0.34) mmol/L, (1.69±0.21) mmol/L, and (27.18±2.19) kg/m². The ALB levels and liver/spleen CT ratio in the observation group were higher than those in the control group, while AST, ALT, and traditional Chinese medicine syndrome scores were lower in the observation group, with all differences being statistically significant (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.902, P=0.342). Conclusion　pediatric spleen-strengthening, turbidity-resolving and fat-reducing formula combined with vitamin D can improve clinical efficacy, effectively reduce blood lipid levels and improve liver function in the treatment of metabolic-related fatty liver disease in obese children with spleen deficiency and loss of transportation.

Key words:

Metabolic associated fatty liver disease, Obesity, Pediatric  , spleen-strengthening,  , turbidity-resolving  , and  , fat-reducing  , formula, Vitamin D, Spleen deficiency loss of transport syndrome